To determine if the LivePAR nuclear enrichment assay could identify decreased PARylation associated with cisplatin-mediated reversion and reactivation of BRCA2, we compared the BRCA2 deficient ovarian adenocarcinoma cell line PEO1 with its cisplatin-resistant BRCA2-revertant clone C4-2 [21]. The gene discussed is BRCA2; the disease is ovarian adenocarcinoma.